Literature DB >> 15745782

Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.

Efstathios T Detorakis1, Robert E Engstrom, Robert Wallace, Bradley R Straatsma.   

Abstract

PURPOSE: Iris neovascularization (INV) and anterior chamber angle neovascularization after radiotherapy for uveal melanoma may lead to neovascular glaucoma and enucleation. However, neovascularization of the anterior ocular segment may respond favorably to treatment with panretinal photocoagulation. The purpose of this study was to evaluate the frequency, interval to development, and predisposing factors of anterior ocular segment neovascularization following iodine 125 (I125) brachytherapy for uveal melanoma.
DESIGN: Retrospective, interventional, consecutive case series. PARTICIPANTS: Sixty-five patients (65 eyes), consecutively treated with I125 brachytherapy for uveal melanoma from 1995 through 2000 and followed up after radiation therapy for 24 months or more.
METHODS: Clinical findings and ultrasonography characteristics as well as treatment parameters were analyzed. MAIN OUTCOME MEASURES: The frequency of INV was determined and the interval to development of INV as well as the predisposing factors were analyzed statistically.
RESULTS: In 15 of 65 eyes (23%), INV was detected after I125 brachytherapy at a mean +/- standard deviation of 26.66+/-11.63 months (median, 24 months; range, 9-48 months). Risk factors displaying the stronger correlation with INV were greater maximal tumor height (P<0.01), greater tumor vascularity (P<0.01), and disinsertion of horizontal rectus muscles (P = 0.01).
CONCLUSIONS: After I125 brachytherapy for choroidal melanoma, INV developed in 23% of eyes and was correlated with larger tumor size, greater tumor vascularity, and disinsertion of a horizontal rectus muscle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15745782     DOI: 10.1016/j.ophtha.2004.09.028

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.

Authors:  Ilkka Puusaari; Bertil Damato; Tero Kivelä
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  Ocular complications with the use of radium-223: a case series.

Authors:  Julie R Bloom; Alexandra G Castillejos; Brianna Jones; Nimesh Patel; Barry S Rosenstein; Richard G Stock
Journal:  Radiat Oncol       Date:  2022-05-17       Impact factor: 4.309

3.  Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 Posterior Uveal Melanoma: Clinical Outcomes in 158 Patients.

Authors:  Benjamin A King; Caroline Awh; Brad T Gao; Jiajing Wang; Mehmet Kocak; Vanessa M Morales-Tirado; Matthew T Ballo; Matthew W Wilson
Journal:  Ocul Oncol Pathol       Date:  2019-01-10

4.  Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma.

Authors:  Irena Tsui; Robert M Beardsley; Tara A McCannel; Scott C Oliver; Melissa W Chun; Steve P Lee; Phillip E Chow; Nzhde Agazaryan; Fei Yu; Bradley R Straatsma
Journal:  Open Ophthalmol J       Date:  2015-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.